Cargando…
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravi...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082593/ https://www.ncbi.nlm.nih.gov/pubmed/29794828 http://dx.doi.org/10.1097/QAD.0000000000001894 |
| _version_ | 1783345829725077504 |
|---|---|
| author | Sax, Paul E. DeJesus, Edwin Crofoot, Gordon Ward, Douglas Benson, Paul Dretler, Robin Mills, Anthony Brinson, Cynthia Wei, Xuelian Collins, Sean E. Cheng, Andrew |
| author_facet | Sax, Paul E. DeJesus, Edwin Crofoot, Gordon Ward, Douglas Benson, Paul Dretler, Robin Mills, Anthony Brinson, Cynthia Wei, Xuelian Collins, Sean E. Cheng, Andrew |
| author_sort | Sax, Paul E. |
| collection | PubMed |
| description | A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated. |
| format | Online Article Text |
| id | pubmed-6082593 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60825932018-08-17 Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide Sax, Paul E. DeJesus, Edwin Crofoot, Gordon Ward, Douglas Benson, Paul Dretler, Robin Mills, Anthony Brinson, Cynthia Wei, Xuelian Collins, Sean E. Cheng, Andrew AIDS Research Letter A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated. Lippincott Williams & Wilkins 2018-07-31 2018-06-18 /pmc/articles/PMC6082593/ /pubmed/29794828 http://dx.doi.org/10.1097/QAD.0000000000001894 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Research Letter Sax, Paul E. DeJesus, Edwin Crofoot, Gordon Ward, Douglas Benson, Paul Dretler, Robin Mills, Anthony Brinson, Cynthia Wei, Xuelian Collins, Sean E. Cheng, Andrew Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title_full | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title_fullStr | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title_full_unstemmed | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title_short | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| title_sort | coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082593/ https://www.ncbi.nlm.nih.gov/pubmed/29794828 http://dx.doi.org/10.1097/QAD.0000000000001894 |
| work_keys_str_mv | AT saxpaule coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT dejesusedwin coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT crofootgordon coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT warddouglas coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT bensonpaul coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT dretlerrobin coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT millsanthony coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT brinsoncynthia coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT weixuelian coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT collinsseane coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide AT chengandrew coformulatedbictegraviremtricitabinetenofoviralafenamideafterinitialtreatmentwithbictegravirordolutegravirandemtricitabinetenofoviralafenamide |